Andy is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology and healthcare.
Prior to Section 32, Andy was in leadership roles at Verily Life Sciences (previously Google Life Sciences) and X (previously GoogleX). Andy was the Global Head of Business and Corporate Development and a member of the executive leadership team at Verily. His team executed global go-to-market campaigns for a wide range of next-generation healthcare technologies building creative and pioneering partnerships, collaborations and joint ventures with some of the world’s top companies. Andy’s efforts directly contributed to Verily’s rapid scale, multi-billion dollar financing rounds and Verily’s efforts to address the opioid and Covid-19 epidemics.
Andy also co-founded the Verily Ventures program to make early-stage investments at the nexus of advanced technologies and healthcare. Under his stewardship, the program generated top-tier venture returns.
At GoogleX, Andy worked with a variety of projects across automation, quantum computing, life sciences, machine learning, artificial intelligence, and other technology disciplines. He continues to serve as an advisor to various teams at X.
Prior to Google, Andy helped build and scale two businesses. One firm was seeded by Stanford University’s Endowment, which was successfully acquired while the second — a health-care oriented private equity and credit firm — is still active in San Francisco. He started his career at RBC Ventures at a fund which was a part of the DFJ Global Network.
Andy is a patented inventor with an Undergraduate Degree in Biochemical Engineering from McGill University and a Master in Biomedical Engineering from Cornell University. He also holds the Chartered Financial Analyst designation.
- - Ciitizen
- - Cortexyme (CRTX)
- - Culture Biosciences
- - Cohere
- - Current Health
- - Faro Health
- - Mammoth Biosciences
- - Nusano
- - Oscar (OSCR)
- - Phaidra
- - Syllable
- - Verve (VERV)